REG-Arix Bioscience PLC Unaudited NAV for December 2022

Arix BioscienceAnnouncement

30/01/2023 07:00

============

   Arix Bioscience PLC (ARIX)
   Unaudited NAV for December 2022

   30-Jan-2023 / 07:00 GMT/BST
   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

                              Arix Bioscience plc

                                        

                        Unaudited NAV for December 2022

    

   LONDON, 30 January  2023: Arix  Bioscience plc (“Arix”  or the  “Company”)
   (LSE: ARIX),  a global  venture capital  company focused  on investing  in
   breakthrough biotechnology companies,  announces the  unaudited Net  Asset
   Value (“NAV”)  of the  Company for  the  date ended  31 December  2022  as
   follows:

    

                                NAV Breakdown                             
                                                               Total
       Date        Listed      Unlisted              Other      NAV     NAV
                  Portfolio   Portfolio    Cash    Interests            per
                                                                       share
    31 December
       2022        £47.0m       £56.2m    £123.4m    £3.0m    £229.6m  £1.78

    (unaudited)

    

    

                                      ENDS 

    

   Enquiries

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   +44 (0)20 7290 1050

   ir 1 @arixbioscience.com

    

   Powerscourt Group

   Sarah MacLeod, Ibrahim Khalil, Nick Johnson

   +44 (0)20 7250 1446

    2 arix@powerscourt-group.com

    

   About Arix Bioscience plc

   Arix Bioscience  plc  is  a  global venture  capital  company  focused  on
   investing in  breakthrough  biotechnology  companies  around  cutting-edge
   advances in life sciences.

    

   We collaborate  with exceptional  entrepreneurs and  provide the  capital,
   expertise, and  global  networks  to  help  accelerate  their  ideas  into
   important new treatments for patients. As a listed company, we are able to
   bring this exciting  growth phase of  our industry to  a broader range  of
   investors.  3 www.arixbioscience.com

    

    

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  NAV
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   219090
   EQS News ID:    1545893


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    4 fncls.ssp?fn=show_t_gif&application_id=1545893&application_name=news&site_id=reuters9

References

   Visible links
   1. mailto:charlotte@arixbioscience.com
   2. mailto:arix@powerscourt-group.com
   3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1545893&site_id=reuters9&application_name=news


============